Hanmi Pham made a presentation on its next generation targeted cancer drug at the American Association for Cancer Research

제목 없음 Apr 18~22, 3 preclinical test reports were presented at the American Association for Cancer Research in Philadelphia, USA. The possibility of its becoming the next generation drug-which improves side effects and resistance- was confirmed Hanmi Pham presented 3 preclinical test report of 2 types of next generation cancer drug under development at the American Association for Cancer Research(AACR). Hanmi Pharm made a presentation of the research results on the resistance targeted anti-cancer drug (HM61713) and the next generation RAF inhibitor targeted cancer drug (HM95573) at the American Association for Cancer Research from Apr 18 to Apr 22. First, HM61713 selective inhibits the mutation of signal delivery substance EGFR involved in cancer cell growth, and is evaluated as 3G lung cancer drug which overcomes the resistance and side effects after the administration with Iressa and Tarceva used for treating lung cancer. At this forum, Hanmi Pharm made a presentation on the results of the estimation of the effective dose for human bodies in accordance with HM61713 dose in animal models. Based on this, Hanmi Pharm proceeded with domestic phase 1/2 clinical trial with the lung cancer patients with the resistance to the conventional cancer drug and verified its safety and efficacy. These reports were orally presented at the forum of ASCO held last year. Hanmi Pharm currently proceeds with domestic and global phase 2 clinical trial with the lung cancer patients with the resistance to T790M and domestic phase 2 clinical trial so as to verify if it can be applied to the non-small cell lung cancer patients as the primary treatment. At the same time, Hanmi Pharm presented 2 preclinical test reports on the action mechanism of HM95573 and solid cancers. HM95573 is a new targeted cancer drug which selectively inhibits RAF and is being developed as the next generation drug for the patients suffering side effects and resistance. RAF consists of 3 subtypes (A-RAF, B-RAF, C-RAF), and double B-RAF mutation is known as melanoma pathogenesis. Hanmi has verified the excellent medicinal effect and side effect reducing effect compared with the conventional drugs such as Zelboraf and Tafinlar used as B-RAF mutation inhibitor, and furthermore verified its efficacy for various solid cancers with the involvement of C-RAF. Currently Hanmi proceeds with the clinical trial of HM95573 with the patients with various solid cancers (B-RAF, K-RAS and N-RAS mutations colon cancer, lung cancer, liver cancer) including B-RAF mutation malignant melanoma. Seo, Gui Hyeon, the director of Hanmi Pharm said: “We focus our R&D competence on the development of the next generation targeted cancer drug which innovatively improves the resistance and side effect of the conventional drug. And we will accelerate clinical trials to make innovate treatment for the patients suffering cancer”. | Glossary | American Association for Cancer Research (AACR): The world’s top-class association for cancer research in which about 20,000 clinical experts from about 60 countries participate. It is held in the major cities of the US in Apr every year. EGFR TKI (Epidermal growth factor receptor tyrosine kinase inhibitor): The activated signaling pathways plays a critical role to the growth, differentiation and survival of cancer cells, and tyrosine kinases serves an important mediating enzyme to activate this signaling pathway. EGFR TKI selectively inhibits the tyrosine kinase that is activated in epithelial cell growth factor receptors, thereby inhibiting the survival, proliferation and metastasis of cancer cells. T790M: It refers to a specific protein mutation causing resistance to conventional cancer drug EGFR TKI. RAF: It refers to the protein involved in the formation and induction of tumor, being composed of 3 subtypes: A-RAF, B-RAF and C-RAF. Variant B-RAF is involved in the formation of tumor and B-RAF mutation, in particular, is known to induce various cancerous tumors. RAS: It refers to the protein involved in the formation and induction of tumors, being composed of 3 subtypes: H-RAS, K-RAS and N-RAS. Of variant RAS, K-RAS and N-RAS mutations are known to influence the formation of tumors. PREV Eli Lilly & Co.’s CEO John Lechleiter meets Hanmi’s Chairman Lim, Sung Ki LIST NEXT All the 3 strengths of ‘Triaxone’ , an antibiotic powder injection are now available to market in EU

The release as fetched from its publisher. hanmipharm.com ↗